| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| W M Glazer, R A Dickso. Clozapine reduces violence and persistent aggression in schizophrenia. The Journal of clinical psychiatry. vol 59 Suppl 3. 1998-04-10. PMID:9541332. |
clozapine reduces violence and persistent aggression in schizophrenia. |
1998-04-10 |
2023-08-12 |
human |
| W M Glazer, R A Dickso. Clozapine reduces violence and persistent aggression in schizophrenia. The Journal of clinical psychiatry. vol 59 Suppl 3. 1998-04-10. PMID:9541332. |
the reduction in violence and persistent aggression with clozapine treatment should improve the chances for integration of the schizophrenia patient into the community and provide cost savings to society. |
1998-04-10 |
2023-08-12 |
human |
| H Y Meltze. Suicide in schizophrenia: risk factors and clozapine treatment. The Journal of clinical psychiatry. vol 59 Suppl 3. 1998-04-10. PMID:9541333. |
suicide in schizophrenia: risk factors and clozapine treatment. |
1998-04-10 |
2023-08-12 |
Not clear |
| D E Case. Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia. The Journal of clinical psychiatry. vol 59 Suppl 3. 1998-04-10. PMID:9541336. |
when clozapine became commercially available for treatment-resistant and treatment-intolerant (i.e., prone to eps and td) schizophrenic individuals, it became apparent that an antipsychotic need not induce motor side effects to be efficacious in reducing the symptomatology of schizophrenia. |
1998-04-10 |
2023-08-12 |
Not clear |
| J A Lieberma. Maximizing clozapine therapy: managing side effects. The Journal of clinical psychiatry. vol 59 Suppl 3. 1998-04-10. PMID:9541337. |
clozapine remains the only antipsychotic with proven efficacy in treatment-resistant schizophrenia. |
1998-04-10 |
2023-08-12 |
Not clear |
| R R Conle. Optimizing treatment with clozapine. The Journal of clinical psychiatry. vol 59 Suppl 3. 1998-04-10. PMID:9541338. |
clozapine is the only antipsychotic agent that is effective in treatment-resistant schizophrenia. |
1998-04-10 |
2023-08-12 |
Not clear |
| W T Carpenter, J M Zito, J Vitrai, J Volavk. Hypothesis testing: is clozapine's superior efficacy dependent on moderate D2 receptor occupancy? Biological psychiatry. vol 43. issue 2. 1998-04-03. PMID:9474440. |
how clozapine exerts superior antipsychotic efficacy in treatment-resistant schizophrenia is not known. |
1998-04-03 |
2023-08-12 |
Not clear |
| R Shiloh, Z Zemishlany, D Aizenberg, M Radwan, B Schwartz, P Dorfman-Etrog, I Modai, M Khaikin, A Weizma. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. The British journal of psychiatry : the journal of mental science. vol 171. 1998-04-03. PMID:9519099. |
sulpiride augmentation in people with schizophrenia partially responsive to clozapine. |
1998-04-03 |
2023-08-12 |
Not clear |
| A E Evins, E T Amico, V Shih, D C Gof. Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. Journal of neural transmission (Vienna, Austria : 1996). vol 104. issue 6-7. 1998-03-10. PMID:9444574. |
to examine whether serum excitatory amino acid concentrations change with clozapine treatment and whether these changes correlate with improvement in negative symptoms, serum excitatory amino acids were measured and clinical scales administered in seven subjects with schizophrenia before and after switching from conventional neuroleptics to clozapine. |
1998-03-10 |
2023-08-12 |
human |
| D L Fogelson, H Sternbach, D Payn. A naturalistic pilot study comparing haloperidol, clozapine, sertindole, and risperidone in partially responsive chronic schizophrenia or schizoaffective disorder. Journal of clinical psychopharmacology. vol 17. issue 6. 1998-02-06. PMID:9408817. |
a naturalistic pilot study comparing haloperidol, clozapine, sertindole, and risperidone in partially responsive chronic schizophrenia or schizoaffective disorder. |
1998-02-06 |
2023-08-12 |
Not clear |
| M D Combs, P J Perry, K A Beve. N-desmethylclozapine, an insensitive marker of clozapine-induced agranulocytosis and granulocytopenia. Pharmacotherapy. vol 17. issue 6. 1998-01-30. PMID:9399615. |
we reviewed the charts of 58 patients with treatment-refractory schizophrenia who were receiving clozapine, to determine if the drug's active metabolite, n-desmethylclozapine, is a biologic marker for impending clozapine-induced granulocytopenia and agranulocytosis. |
1998-01-30 |
2023-08-12 |
Not clear |
| D P Birket. Clozapine compared with haloperidol for refractory schizophrenia. The New England journal of medicine. vol 338. issue 4. 1998-01-22. PMID:9441246. |
clozapine compared with haloperidol for refractory schizophrenia. |
1998-01-22 |
2023-08-12 |
Not clear |
| N R Schoole. New antipsychotic medications: strategies for evaluation and selected findings. Schizophrenia research. vol 27. issue 2-3. 1998-01-21. PMID:9416654. |
the unprecedented level of activity in the development of new antipsychotic medications can be traced to the 1989 approval of clozapine by the us food and drug administration for treatment of refractory schizophrenia. |
1998-01-21 |
2023-08-12 |
Not clear |
| A M Walker, L L Lanza, F Arellano, K J Rothma. Mortality in current and former users of clozapine. Epidemiology (Cambridge, Mass.). vol 8. issue 6. 1998-01-15. PMID:9345668. |
because it can induce agranulocytosis, however, clozapine is indicated only for schizophrenia that is not responsive to other therapies. |
1998-01-15 |
2023-08-12 |
Not clear |
| G Mas. Atypical neuroleptics in the treatment of early onset schizophrenia. Panminerva medica. vol 39. issue 3. 1998-01-13. PMID:9360425. |
the aim of this critical review is to describe clinical use of atypical neuroleptics clozapine and risperidone in children and adolescents with early-onset schizophrenia. |
1998-01-13 |
2023-08-12 |
Not clear |
| K E Wong, S A Chong, F Ngui, M Winslow, G S Devan, O K Leong, C H Cho. Initial experience with clozapine in Woodbridge Hospital. Singapore medical journal. vol 38. issue 8. 1998-01-08. PMID:9364887. |
this study was performed to evaluate the efficacy and side-effect profile of the atypical neuroleptic clozapine in local asian patients with treatment-resistant schizophrenia. |
1998-01-08 |
2023-08-12 |
Not clear |
| M Maes, E Bosmans, G Kenis, R De Jong, R S Smith, H Y Meltze. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophrenia research. vol 26. issue 2-3. 1998-01-06. PMID:9323354. |
in vivo immunomodulatory effects of clozapine in schizophrenia. |
1998-01-06 |
2023-08-12 |
human |
| J Martín, J C Gómez, E García-Bernardo, M Cuesta, E Alvarez, M Gurpegu. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. The Journal of clinical psychiatry. vol 58. issue 11. 1998-01-06. PMID:9413413. |
clozapine is currently the treatment of choice for neuroleptic-resistant schizophrenia. |
1998-01-06 |
2023-08-12 |
Not clear |
| Y Raoul, P Manesse, M Delag. [Quality of life of schizophrenic patients and clozapine]. L'Encephale. vol 23 Spec No 4. 1997-12-30. PMID:9417398. |
using a 'subjective quality of life profile' by gerin et al., the authors interviewed 22 patients presenting with 'recalcitrant schizophrenia' and treated with clozapine for more than 3 years. |
1997-12-30 |
2023-08-12 |
Not clear |
| O Gosselin, J M Ribeyre, J P Kah. [Atypical pharmacologic characteristics of an antipsychotic drug: clozapine]. L'Encephale. vol 23 Spec No 4. 1997-12-30. PMID:9417400. |
the discovery of clozapine in the mid-sixties and the demonstration of its clinical efficacy vis-à-vis recalcitrant schizophrenia contributed to the development of specific psychopharmacological research addressing the concept of atypical antipsychotics. |
1997-12-30 |
2023-08-12 |
Not clear |